Akoustis Technologies Inc expected to post a loss of 25 cents a share - Earnings Preview

Aktis Oncology

03/02/2023 14:50

* Akoustis Technologies Inc  AKTS.OQ   AKTS.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
7. 
    * The Huntersville North Carolina-based  company is expected
to
report  a 61.2% increase in revenue to $5.92 million from $3.67
million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Akoustis
Technologies Inc
is for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akoustis
Technologies Inc is $7​, above​ its last closing price of $4.07.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.22       -0.20      -0.28     Missed  -38.3
 Jun. 30 2022              -0.19      -0.26     Missed  -34.5
 Mar. 31 2022  -0.23       -0.22      -0.22     Met     0​
 Dec. 31 2021  -0.22       -0.20      -0.23     Missed  -12.2
 ​​Sep.        -0.20       -0.20      -0.25     Missed  -27.1
 30 2021                                                
 Jun. 30 2021  -0.21       -0.19      -0.23     Missed  -23.2​
 Mar. 31 2021  -0.27       -0.28      -0.22     Beat    20.5
 Dec. 31 2020  -0.25       -0.23      -0.22     Beat    6.4
 This summary was machine generated February 3 at 14:50 GMT.  All
figures in US dollars  unless otherwise stated